Begin main content

Additional Resources

Date: July 20, 2017
Result type: Resources

Canadian Government and Association Resources

Journal articles

  • Fischer et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017; e1. dx.doi.org/10.2105/AJPH.2017.303818.
  • Wettlaufer et al. Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence; 2017;173:185-190. dx.doi.org/10.1016/j.drugalcdep.2016.12.024
  • Devinsky et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med; 2017;376:2011-2020. dx.doi.org/10.1056/NEJMoa1611618
  • West, JC. Medical marijuana: Challenges and risk issues for health care providers. J of Healthcare Risk Mgmt; 2017;36:38-43. dx.doi.org/10.1002/jhrm.21267
  • Hazekamp A, Heerdink, ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol; 2013 Aug;69(8):1575-80. ncbi.nlm.nih.gov/pubmed/23588562
  • Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. ncbi.nlm.nih.gov/pubmed/24175484
  • Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis - the Canadian perspective. J Pain Res 2016; 9:735-44. ncbi.nlm.nih.gov/pmc/articles/PMC5053383 
  • Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014 Dec; 60(12):1083-90. ncbi.nlm.nih.gov/pmc/articles/PMC4264803/
  • Lucas, P. Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain, Journal of Psychoactive Drugs, 2012, 44:2, 125-133. doi:10.1080/02791072.2012.684624
  • Lucas et al. Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research and Theory, 2013, 21(5): 435–442. dx.doi.org/10.3109/16066359.2012.733465
  • Lucas et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2015. ncbi.nlm.nih.gov/pubmed/26364922.
  • Lucas, P., Walsh, Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 2017, 42, 30–35. ncbi.nlm.nih.gov/pubmed/28189912
  • Rubin, R. Medical marijuana is legal in most states, but physicians have little evidence to guide them. JAMA. 2017; 317(16):1611-1613. jamanetwork.com/journals/jama/fullarticle/2617326

Systematic Reviews

Policy Statements and Guidance

Canada

International